# A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

> **NCT04689204** · EARLY_PHASE1 · COMPLETED · sponsor: **He Huang** · enrollment: 3 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** CTA30X

## Key facts

- **NCT ID:** NCT04689204
- **Lead sponsor:** He Huang
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-29
- **Primary completion:** 2022-12-29
- **Final completion:** 2024-05-31
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04689204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04689204, "A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04689204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*